Accéder au contenu
Merck

C2538

Carboplatin

DNA cross-linking agent, powder

Synonyme(s) :

cis-Diammine(1,1-cyclobutanedicarboxylato) platinum

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

A propos de cet article

Formule linéaire :
[C4H6(CO2)2]Pt(NH3)2
Numéro CAS:
41575-94-4
Poids moléculaire :
371.25
NACRES:
NA.77
PubChem Substance ID:
24278303
UNSPSC Code:
12352200
EC Number:
255-446-0
MDL number:
MFCD00070464
Form:
powder
Quality level:
100

Principaux documents

Voir toute la documentation
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider

Nom du produit

Carboplatin,

InChI key

OLESAACUTLOWQZ-UHFFFAOYSA-L

InChI

1S/C6H8O4.2H3N.Pt/c7-4(8)6(5(9)10)2-1-3-6;;;/h1-3H2,(H,7,8)(H,9,10);2*1H3;/q;;;+2/p-2

SMILES string

N.N.O=C1O[Pt]OC(=O)C12CCC2

form

powder

antibiotic activity spectrum

neoplastics

originator

Bristol-Myers Squibb

Quality Level

100

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

General description

Carboplatin is used to treat testicular, ovarian and breast cancer.

Application

Carboplatin has been used:
  • in chemotherapy-induced thrombocytopenia mouse model and treatment
  • to induce cell death in a large subset of colorectal cancer cells
  • in the evaluation of cell proliferation and chemosensitivity
  • as a positive control for suppressed cell growth

Biochem/physiol Actions

Carboplatin is a platinum-based antineoplastic drug that damages DNA by forming intrastrand cross-links with neighboring guanine residues. Tumors acquire resistance to these drugs through the loss of DNA-mismatch repair (MMR) activity and the resultant decrease in the induction of programmed cell death.

Features and Benefits

This compound is a featured product for Apoptosis research. Click here to discover more featured Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Bristol-Myers Squibb. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Danger

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Muta. 1B - Repr. 1B - Resp. Sens. 1 - Skin Sens. 1

Classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number
MKCZ0527
MKCW1333
MKCT7823
MKCR3593
MKCR8746

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Rechercher un(e) COA

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Joel Shapiro et al.
Annals of surgery, 258(5), 678-688 (2013-10-08)
To gain insight into the exact location of residual esophageal cancer in the esophageal wall and regional lymph nodes after neoadjuvant chemoradiotherapy (nCRT) and to determine the pattern of regression. Data from the recently published chemoradiotherapy for oesophageal cancer followed
Osteoblasts support megakaryopoiesis through production of interleukin 9
Xiao M, et al.
Blood, blood-b2016 (2017)
Furqan Shaikh et al.
Pediatric blood & cancer, 60(4), 587-592 (2012-09-15)
While cisplatin is considered superior to carboplatin for the treatment of malignant germ cell tumors (MGCTs) in adults, pediatric oncology collaborative groups still remain concerned about the late effects of cisplatin in children. We performed a literature search to identify
Michael D Nyquist et al.
Cell reports, 31(8), 107669-107669 (2020-05-28)
Prostate cancers (PCs) with loss of the potent tumor suppressors TP53 and RB1 exhibit poor outcomes. TP53 and RB1 also influence cell plasticity and are frequently lost in PCs with neuroendocrine (NE) differentiation. Therapeutic strategies that address these aggressive variant
Mun Sem Liew et al.
BJU international, 112 Suppl 2, 74-82 (2013-10-30)
To review time-trends in the use of perioperative chemotherapy and its impact on oncological outcomes in patients with bladder urothelial cancer (UC) at a single tertiary institution. Using electronic and paper medical records, 89 patients were identified who underwent radical
Afficher tous les articles scientifiques apparentés

Contenu apparenté

Product Information Sheet - C2538

Product Information Sheet

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique